• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在慢性肾病患者中,较低的甲状旁腺激素(PTH)控制水平是否与较低水平的炎性细胞因子相关?

Is it true that lower PTH control is associated with lower levels of inflammatory cytokines in patients with chronic kidney disease?

作者信息

Qin Xu, Shasha Wang, Qiuyue Xiong, Ning Wang, Yifeng Hu, Lei Yan, Huixia Cao, Fengmin Shao

机构信息

Department of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Henan, China.

Department of Nephrology, Key Laboratory of Nephrology and Immunology, Henan Xinxiang Medical University and Henan Provincial People's Hospital, Henan, China.

出版信息

Ann Med. 2025 Dec;57(1):2541080. doi: 10.1080/07853890.2025.2541080. Epub 2025 Aug 9.

DOI:10.1080/07853890.2025.2541080
PMID:40781972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12337739/
Abstract

BACKGROUND

The body of patients with chronic kidney disease (CKD)is in a state of microinflammation, which further aggravates the progression of CKD and the occurrence and development of its complications. The inflammatory state of the body is significantly increased in patients with secondary hyperparathyroidism of CKD.

METHODS

Patients diagnosed with chronic kidney disease in the department of Nephrology of Henan Provincial People's Hospital were selected as the experimental group, and 58 normal subjects were selected as the control group. Collecting patient's Clinical date, whole blood of the experimental group and control group was collected, and hs-CRP was detected by enzyme-linked immunosorbent assay. Compare the differences in clinical indicators and serum hs-CRP between the two groups. Taking PTH and hs-CRP as dependent variables, correlation analysis was conducted to clarify the relationship between PTH and hs-CRP, and further curve fitting was carried out.

RESULTS

The levels of hemoglobin, total protein and albumin in CKD group were significantly lower than those in control group ( < 0.001). Alkaline phosphatase, creatinine, uric acid, Cyc and blood phosphorus in CKD group were higher than those in control group, and the values were 0.016, <0.001, <0.001, <0.001, <0.001, respectively. Blood calcium was lower than control group,  < 0.001. The levels of hs-CRP in CKD group were significantly higher than those in control group,  < 0.001. Serum PTH was positively correlated with serum hs-CRP ( = 0.299,  = 0.002) in a normalized holistic analysis of CKD patients. In order to further clarify the correlation between PTH and hs-CRP, quadratic method was used to conduct curve fitting on PTH and hs-CRP and found that  = 0.361,  = 7.795,  < 0.001. Quadratic method was used to quadratic curve fitting at PTH levels <600 pg/mL, <500 pg/mL, <400 pg/mL, <300 pg/mL and <200 pg/mL, respectively, and it was found that the corresponding  = 0.281,  = 4.158,  < 0.001.  = 0.292,  = 4.397,  < 0.001;  = 0.546,  = 18.456,  < 0.001;  = 0.415,  = 7.471,  < 0.001;  = 0.403,  = 5.220,  < 0.001. It was found that there was no correlation between PTH and hs-CRP in hemodialysis patients and peritoneal dialysis patients. In order to exclude the influence of drug use on the statistical results, after excluding the patients who took over phosphorus binder and calcium binder, curve fitting method was used to find that PTH and CRP were correlated, in peritoneal dialysis group and hemodialysis group,  = 0.953,  = 39.913,  < 0.001;  = 0.448,  = 3.391,  = 0.010 respectively.

CONCLUSION

CKD patients have the lowest levels of inflammatory factors within a certain range of PTH.

摘要

背景

慢性肾脏病(CKD)患者机体处于微炎症状态,这进一步加重了CKD的进展及其并发症的发生发展。CKD继发性甲状旁腺功能亢进患者机体的炎症状态显著升高。

方法

选取河南省人民医院肾内科确诊为慢性肾脏病的患者作为实验组,选取58例正常受试者作为对照组。收集患者临床资料,采集实验组和对照组全血,采用酶联免疫吸附法检测超敏C反应蛋白(hs-CRP)。比较两组临床指标及血清hs-CRP的差异。以甲状旁腺激素(PTH)和hs-CRP为因变量进行相关性分析,明确PTH与hs-CRP之间的关系,并进一步进行曲线拟合。

结果

CKD组血红蛋白、总蛋白和白蛋白水平显著低于对照组(<0.001)。CKD组碱性磷酸酶、肌酐、尿酸、胱抑素C(Cyc)和血磷高于对照组,P值分别为0.016、<0.001、<0.001、<0.001、<0.001。血钙低于对照组,P<0.001。CKD组hs-CRP水平显著高于对照组,P<0.001。在对CKD患者进行的标准化整体分析中,血清PTH与血清hs-CRP呈正相关(r=0.299,P=0.002)。为进一步明确PTH与hs-CRP之间的相关性,采用二次曲线法对PTH和hs-CRP进行曲线拟合,发现r=0.361,F=7.795,P<0.001。分别采用二次曲线法在PTH水平<600 pg/mL、<500 pg/mL、<400 pg/mL、<300 pg/mL和<200 pg/mL时进行二次曲线拟合,发现相应的r=0.281,F=4.158,P<0.001;r=0.292,F=4.397,P<0.001;r=0.546,F=18.456,P<0.001;r=0.415,F=7.471,P<0.001;r=0.403,F=5.220,P<0.001。发现血液透析患者和腹膜透析患者中PTH与hs-CRP无相关性。为排除药物使用对统计结果的影响,排除服用过磷结合剂和钙结合剂的患者后,采用曲线拟合方法发现腹膜透析组和血液透析组中PTH与CRP相关,r分别为0.953,F=39.913,P<0.001;r=0.448,F=3.391,P=0.010。

结论

在一定PTH范围内,CKD患者炎症因子水平最低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/cf8ca9f38670/IANN_A_2541080_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/b110f2ba9efd/IANN_A_2541080_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/76aad2a988f0/IANN_A_2541080_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/cf8ca9f38670/IANN_A_2541080_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/b110f2ba9efd/IANN_A_2541080_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/76aad2a988f0/IANN_A_2541080_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/409a/12337739/cf8ca9f38670/IANN_A_2541080_F0003_C.jpg

相似文献

1
Is it true that lower PTH control is associated with lower levels of inflammatory cytokines in patients with chronic kidney disease?在慢性肾病患者中,较低的甲状旁腺激素(PTH)控制水平是否与较低水平的炎性细胞因子相关?
Ann Med. 2025 Dec;57(1):2541080. doi: 10.1080/07853890.2025.2541080. Epub 2025 Aug 9.
2
Interventions for metabolic bone disease in children with chronic kidney disease.慢性肾脏病患儿代谢性骨病的干预措施。
Cochrane Database Syst Rev. 2015 Nov 12;2015(11):CD008327. doi: 10.1002/14651858.CD008327.pub2.
3
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
4
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
5
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.拟钙剂用于慢性肾病患者继发性甲状旁腺功能亢进的治疗
Cochrane Database Syst Rev. 2014;2014(12):CD006254. doi: 10.1002/14651858.CD006254.pub2. Epub 2014 Dec 9.
6
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
7
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.慢性肾病患者矿物质和骨紊乱的饮食干预措施
Cochrane Database Syst Rev. 2015 Sep 16;2015(9):CD010350. doi: 10.1002/14651858.CD010350.pub2.
8
Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.药物对血清甲状旁腺激素、磷和钙水平的影响与 CKD 患者死亡率的关系:一项荟萃分析。
Am J Kidney Dis. 2015 Dec;66(6):962-71. doi: 10.1053/j.ajkd.2015.03.036. Epub 2015 May 21.
9
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3.
10
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.

本文引用的文献

1
Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat.肾性贫血患者尿液的蛋白质组学和代谢组学综合分析揭示了罗沙司他的分子机制。
Mol Omics. 2023 Jul 10;19(6):473-483. doi: 10.1039/d3mo00015j.
2
Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019.三十年来慢性肾脏病流行病学模式的变化趋势:2019 年全球疾病负担研究的更新分析。
BMJ Open. 2023 Mar 17;13(3):e064540. doi: 10.1136/bmjopen-2022-064540.
3
Chronic kidney disease-induced muscle atrophy: Molecular mechanisms and promising therapies.
慢性肾脏病所致肌肉萎缩:分子机制与前景广阔的治疗方法
Biochem Pharmacol. 2023 Feb;208:115407. doi: 10.1016/j.bcp.2022.115407. Epub 2022 Dec 31.
4
Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure.磷和甲状旁腺激素在慢性肾衰竭实验模型中心脏肥大和纤维化发展中的作用。
Nefrologia (Engl Ed). 2021 Nov-Dec;41(6):640-651. doi: 10.1016/j.nefroe.2021.12.004. Epub 2022 Jan 3.
5
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.针对慢性肾脏病和心血管疾病中由先天免疫驱动的炎症
Nat Rev Nephrol. 2022 Dec;18(12):762-778. doi: 10.1038/s41581-022-00621-9. Epub 2022 Sep 5.
6
CKD-MBD biomarkers and CKD progression: an analysis by the joint model.慢性肾脏病-矿物质和骨异常生物标志物与慢性肾脏病进展:联合模型分析
Nephrol Dial Transplant. 2023 Mar 31;38(4):932-938. doi: 10.1093/ndt/gfac212.
7
Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.缺氧诱导因子(HIF)稳定剂罗沙司他治疗血液透析患者肾性贫血的短期临床研究。
In Vivo. 2022 Jul-Aug;36(4):1785-1789. doi: 10.21873/invivo.12892.
8
Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.接受透析治疗的患者中慢性肾脏病-矿物质和骨异常(CKD-MBD)与营养不良-炎症复合征(MICS)之间新出现的相互作用。
Clin Exp Nephrol. 2022 Jul;26(7):613-629. doi: 10.1007/s10157-022-02216-x. Epub 2022 Mar 30.
9
Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease.利用机器学习评估慢性肾脏病患者微炎症在心血管事件中的作用。
Front Immunol. 2022 Jan 10;12:796383. doi: 10.3389/fimmu.2021.796383. eCollection 2021.
10
Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.近期和新兴的慢性肾脏病贫血铁缺乏症治疗方法:综述。
Am J Kidney Dis. 2022 Jun;79(6):868-876. doi: 10.1053/j.ajkd.2021.09.017. Epub 2021 Nov 7.